X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/acadia-pharmaceuticals-schizophrenia-drug-fails-late-stage-study-2024-03-11/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214925
https://acadia.com/media/news-releases/delaware-federal-district-court-rules-in-favor-of-acadia-pharmaceuticals-in-nuplazid-pimavanserin-patent-litigation/
https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-label-update-for-nuplazid-pimavanserin/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214782
https://endpts.com/acadia-hits-another-nuplazid-roadblock-as-the-fda-doles-out-crl-and-recommends-another-trial/
https://www.fool.com/investing/2022/06/21/why-acadia-pharmaceuticals-stock-is-crashing-today/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214925
https://www.fiercepharma.com/pharma/after-shocking-fda-about-face-acadia-revives-nuplazid-narrower-alzheimer-s-focus
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cadila-healthcares-us-arm-receives-fda-nod-to-market-pimavanserin-capsule/articleshow/88615551.cms
https://www.marketscreener.com/quote/stock/ACADIA-PHARMACEUTICALS-IN-8222/news/Acadia-Pharmaceuticals-to-Resubmit-Supplemental-New-Drug-Application-for-Pimavanserin-Shares-Declin-37388921/
https://www.expresspharma.in/zydus-cadila-receives-tentative-approval-from-us-fda-for-pimavanserin-tablets/
https://www.businesswire.com/news/home/20210603005317/en/NUPLAZID%C2%AE-pimavanserin-Efficacy-Data-from-Open-Label-Extension-OLE-Study-Published-in-Parkinsonism-and-Related-Disorders
https://www.fiercepharma.com/pharma/acadia-surprise-nuplazid-letter-from-fda-and-subsequent-cold-shoulder-begs-more-questions
https://www.businesswire.com/news/home/20200825005405/en/ACADIA-Pharmaceuticals-Acquires-CerSci-Therapeutics-Adds-Pain#:~:text=ACADIA%20Pharmaceuticals%20Acquires%20CerSci%20Therapeutics%2C%20Adds%20Novel%20Pain%20Program%20to%20Portfolio,-%2D%20First%2Din%2D&text=This%20acquisition%20strengthens%20ACADIA's%20clinical,seen%20with%20current%20opioid%20treatments.
https://www.neurologylive.com/conferences/aaic-2020/pimavanserin-reduces-dementiarelated-psychosis-symptoms
https://endpts.com/acadias-shot-at-beating-a-fickle-major-depression-challenge-misses-the-mark-in-a-failed-phiii/
https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-announces-us-fda-accepted-filing?field_nir_news_date_value%5Bmin%5D=
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-nuplazid-210793-pimavanserin-capsules-34-mg-tablets-10-mg-1592887299.pdf
https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-submits-supplemental-new-drug-application
https://www.businesswire.com/news/home/20200521005146/en
https://endpts.com/fresh-off-positive-nuplazid-data-acadia-adds-new-clinical-drug-from-vanderbilt-in-milestone-heavy-deal/
https://www.fiercepharma.com/pharma/acadia-s-nuplazid-could-have-blockbuster-hopes-strong-data-psychosis-analyst
https://www.fiercepharma.com/pharma/acadia-s-nuplazid-hits-big-win-schizophrenia-after-past-disappointment
https://www.fiercepharma.com/pharma/acadia-calls-off-nuplazid-dementia-related-psychosis-trial-after-promising-interim-results
https://www.biospace.com/article/acadia-pharma-s-parkinson-s-drug-nuplazid-drug-flunks-clinical-trial-for-schizophrenia/
https://in.reuters.com/article/us-acadia-pharm-study/acadias-schizophrenia-treatment-misses-late-stage-main-goal-shares-fall-16-idINKCN1UH2D5
https://www.businesswire.com/news/home/20190518005003/en/ACADIA-Pharmaceuticals-Present-Phase-2-CLARITY-Results/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.fiercepharma.com/pharma/acadia-discloses-doj-probe-over-nuplazid-marketing
https://endpts.com/acadias-nuplazid-just-clears-main-goal-in-depression-study-with-controversial-design/
https://www.cnbc.com/2018/04/25/acadia-shares-plunge-on-report-fda-is-re-examining-its-drug.html
https://www.fiercepharma.com/pharma/fda-strikes-up-review-acadia-s-nuplazid-after-report-highlights-hundreds-deaths
https://www.dddmag.com/news/2017/10/acadia-pharmaceuticals-initiates-phase-iii-study-pimavanserin-dementia-related-psychosis
http://www.biospace.com/News/rumors-have-pfizer-eyeing-this-socal-biotech/443294/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.nasdaq.com/article/acadia-pharmaceuticals-inc-acad-flirts-with-a-pfizer-inc-pfe-buyout-cm729528
http://www.nasdaq.com/article/akba-inks-blockbuster-deal-agn-on-buying-spree-tsro-gets-fda-date-20161220-01025
Market Place
Share 
